Thermo Fisher Scientific has completed the $1.1 billion sale of its microbiology business to private equity firm Astorg, creating a new independent global diagnostics platform.
The transaction is more than a portfolio divestiture; it highlights how specialized diagnostics assets are increasingly being repositioned for focused growth.
Key takeaways:
• A scaled platform emerges: The business will operate independently with ~2,400 employees and 13 manufacturing and R&D sites globally, providing microbiology diagnostics across clinical, pharmaceutical and food-safety applications.
• Strong financial foundation: The microbiology unit generated approximately $645 million in revenue in 2025, up 2% year-over-year, giving Astorg a sizeable platform with established customers and global infrastructure.
• Leadership reset: Dirk Bontridder, former CEO of PerkinElmer, will lead the new company as CEO, bringing deep experience across diagnostics, life sciences and industrial technology.
• Focused ownership can accelerate growth: As an independent company, the business can potentially prioritize innovation, portfolio expansion, commercial execution and strategic partnerships without competing for capital within a diversified scientific-instruments portfolio.
• Competitive intensity is rising: The microbiology diagnostics landscape includes bioMérieux, Danaher, Merck and Waters, with Waters’ recent combination with BD’s biosciences and diagnostic solutions businesses further reshaping the competitive map.
The broader strategic signal:
For Thermo Fisher, the divestiture unlocks capital and sharpens portfolio focus. For Astorg, it creates an opportunity to build a scaled, independent microbiology diagnostics leader.
The next phase will be defined by how effectively the new company converts its installed base, scientific capabilities and global footprint into innovation-led growth.
In diagnostics, ownership is changing; but the race for scale, specialization and strategic focus is accelerating.
For more details reach us at https://apeloconsulting.com/reports
Email: [email protected]
#ThermoFisherScientific #Astorg #Microbiology #MicrobiologyDiagnostics #Diagnostics #IVD #InVitroDiagnostics #LifeSciences #MedTech #Healthcare #DiagnosticTesting #BioMerieux #Danaher #Merck #Waters #PrivateEquity #HealthcareMAndA #MedTechMAndA #DiagnosticsIndustry #HealthcareStrategy